Carmell Corp. (CTCX): Debt to Book Capitalization Ratio

Corporate company logo of Carmell Corp. (CTCX)

Business diversification from bone regeneration to aesthetics reduces Carmell Corporation (CTCX) dependence on regulators, which is further complemented by innovative plasma materials for rapid tissue healing. The debt-to-equity ratio confirms financial stability, with the indicator standing at 0.00. Management is currently adapting its strategy toward bio-aesthetics, while the market cautiously awaits the commercialization results of new products.

CTCX Carmell Therapeutics: Debt to Book Value in the range 02/21/2024 - 03/10/2025
Manufactured products of Carmell Corp

This ratio measures the degree of business dependence on borrowed capital relative to its book value. For Carmell Corporation (CTCX), which is developing a high-tech ecosystem of regenerative biomaterials, the leverage balance is critical when scaling R&D. By analyzing the current structure of liabilities to book capitalization, an investor assesses default risk against the potential for profitability growth. Moderate leverage confirms the financial stability of this biotech leader, ensuring asset preservation during its expansion into aesthetic medicine.

Competitor analysis

Debts to Book Capitalization ASND (Ascendis Pharma A/S)|Debts to Book Capitalization madrigalpharma.com MDGL|CORT - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio RYTM (Rhythm Pharma)|Akero Therapeutics Inc (AKRO) - Debt to Book Capitalization Ratio|Debt to Book Value Metsera Therapeutics|MLTX (MoonLake Immunotherapeutics) - Debts to Book Capitalization|Debts to Book Capitalization crinetics.com|Debt to Book Value NAMS (NewAmsterdam Pharma Company N.V.)|SLNO (Soleno Therapeutics Inc) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Amicus Pharma FOLD|ETNB - Debt to Book Value|Agios Pharmaceuticals - Debts to Book Capitalization|Debts to Book Value structuretx.com|MDXG (MiMedx) - Debt to Book Value|RZLT: Debt to Book Capital|LXRX (Lexicon Pharma) - Debts to Book Capitalization|Debts to Book Capitalization MBX Corp|Debts to Book Capitalization ALT|Debt to Book Capitalization Ratio AARD (aardvarktherapeutics.com)|Debt to Book Capitalization Ratio Sagimet Biosciences Inc. SGMT|BioAge Labs (BIOA) - Debts to Book Value|BMEA - Debt to Book Capitalization Ratio|QNCX: Debt to Book Capitalization Ratio|GUTS: Debts to Book Capitalization|VTVT - Debts to Net Assets|Debt to Book Capitalization Ratio Agape ATP Corp|Pluri Inc (PLUR) - Debts to Net Assets|Debt to Book Capitalization Ratio Synlogic, Inc. (SYBX)|Debt to Book Value Lipocine Corporation LPCN|Debts to Book Capitalization MTNB (Matinas BioPharma Holdings)|SPRB - Debt to Book Value|Galecto - Debts to Book Capitalization|LUMO - Debts to Book Capitalization|Organovo Holdings Inc (ONVO) - Debt to Book Capitalization Ratio|Radius Pharmaceuticals - Debt to Net Assets Ratio